Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A modular and flexible pipeline for intraoperative electrode reconstruction and localization in patients with brain lesions.

Frontiers in neural circuits·2026
Same author

IDH1-Associated m6A Methylation Is Linked to Transcriptomic Heterogeneity in Glioma.

Cancers·2026
Same author

Comparison between molecular and histological IDH-wild-type glioblastoma and extensive subgroup analysis of IDH-wild-type astrocytic tumors without genomic glioblastoma-defining alterations.

Journal of neuro-oncology·2026
Same author

Acquired genetic and cell-state changes in IDH-mutant glioma progression.

Nature·2026
Same author

Rethinking the role of surgery and radiotherapy in BRAF-mutant papillary craniopharyngioma: a position statement from the neurosurgical perspective.

Neurosurgical focus·2026
Same author

Discrepancies in Inter-Rater Agreement on Resectability of Recurrent Glioblastoma: Complementary Post-hoc Analysis of the Prospective, Randomized DIRECTOR Trial.

Neuro-oncology·2026

Related Experiment Video

Updated: May 9, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Tailored therapy in diffuse gliomas: using molecular classifiers to optimize clinical management.

Jennie W Taylor1, Andrew S Chi, Daniel P Cahill

  • 1Divisions of Neuro-Oncology and Hematology/Oncology, Department of Neurology, Stephen E. and Catherine Pappas Center for Neuro-Oncology, Massachusetts General Hospital Cancer Center; Boston, Massachusetts, USA.

Oncology (Williston Park, N.Y.)
|August 6, 2013
PubMed
Summary

Isocitrate dehydrogenase (IDH) gene mutations and 1p/19q chromosome codeletion are key biomarkers in diffuse gliomas. These genetic markers help predict patient outcomes and guide tailored treatment strategies for brain tumors.

More Related Videos

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
09:17

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

Published on: September 13, 2022

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Related Experiment Videos

Last Updated: May 9, 2026

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma
09:17

Digital Spatial Profiling for Characterization of the Microenvironment in Adult-Type Diffusely Infiltrating Glioma

Published on: September 13, 2022

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model
09:02

Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model

Published on: September 27, 2024

Area of Science:

  • Neuro-oncology
  • Molecular Pathology
  • Genetics

Background:

  • Diffuse gliomas are primary malignant brain tumors with poor prognoses.
  • Significant variability exists in patient outcomes, suggesting underlying biological differences.
  • Recent molecular discoveries are refining glioma classification and understanding.

Purpose of the Study:

  • To review the prognostic and predictive value of IDH mutation and 1p/19q codeletion in diffuse gliomas.
  • To discuss management algorithms incorporating these biomarkers for personalized therapy.
  • To highlight how understanding glioma subtypes and genetic markers can improve survival and reduce treatment morbidity.

Main Methods:

  • Review of current scientific literature and data on IDH mutations and 1p/19q codeletion in gliomas.
  • Analysis of the prognostic significance of these genetic markers.
  • Evaluation of their predictive value for treatment response.
  • Discussion of potential clinical management strategies based on biomarker status.

Main Results:

  • IDH mutations are frequent in low-grade and progressing gliomas, serving as a favorable prognostic marker.
  • 1p/19q codeletion, often in IDH-mutant oligodendrogliomas, predicts chemotherapy responsiveness.
  • These biomarkers offer insights into glioma heterogeneity and clinical behavior.

Conclusions:

  • IDH mutation and 1p/19q codeletion are crucial biomarkers for diffuse gliomas.
  • Incorporating these markers into treatment algorithms can personalize therapy.
  • Tailored treatment based on genetic profiles may optimize survival and minimize adverse effects.